42 unknown, 26 recruiting, 25 completed, 11 not yet recruiting. 76 Phase 2, 32 Phase 3, 8 Phase 1, 4 Not applicable, 2 Phase 4.
Follow XELOX: new trials by email Literature Review of XELOX trials Research Report on XELOX
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma Cadonilimab, CAPOX regimen, Nivolumab - Gastric / Gastroesophageal Junction Adenocarcinoma | Phase 3 | Recruiting | Akeso | 900 | 2026-09-24 | 2026-09-29 |
| Ipilimumab (N01) Plus Sintilimab and Modified XELOX as Conversion Therapy in Unresectable Locally Advanced Gastric Cancer Ipilimumab injection N01, Sintilimab, Modified (60% standard dose) XELOX - Locally Advanced Gastric Cancer | Phase 2 | Not yet recruiting | Chen Lizhu | 30 | 2026-06-15 | 2026-06-10 |
| LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer LDRT, SOX or CAPOX regimen, Tislelizumab - Peritoneal Metastasis of Gastric and Colorectal Cancer, LDRT | Phase 1 | Not yet recruiting | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 9 | 2026-05-01 | 2026-04-27 |
| Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma Tolecizumab (PCSK9 Inhibitor), Sintilimab - Colon Adenocarcinoma | Phase 2 | Recruiting | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 106 | 2026-04-10 | 2026-03-12 |
| Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer SHR-1701, SHR-8068, Short-course radiotherapy - Locally Advanced Colorectal Cancer | Phase 2 | Not yet recruiting | Fudan University | 134 | 2026-04-01 | 2026-03-31 |
| Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer Low-dose radiotherapy, Pucotenlimab, CAPEOX/XELOX - Colorectal Cancer (CRC) | Phase 2 | Recruiting | Sun Yat-sen University | 50 | 2026-03-15 | 2026-10-15 |
| A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation Aipalolitovorelizumab, XELOX + Bevacizumab, mFOLFOX + Bevacizumab - Colorectal Cancer | Phase 2 | Not yet recruiting | Yanqiao Zhang | 30 | 2026-02-01 | 2026-01-08 |
| XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients XELOX (Capecitabine and Oxaliplatin), Dostarlimab - Locally Advanced Rectal Cancer (LARC) | Phase 2 | Not yet recruiting | Gruppo Oncologico Italiano di Ricerca Clinica | 270 | 2026-01-31 | 2026-02-02 |
| Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinomaļ¼A Randomized, Non-comparative Phase 2 Study Adebrelimab, XELOX, SHR-8068 - Gastric Adenocarcinoma, Gastroesophageal Adenocarcinoma | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 30 | 2026-01-30 | 2026-01-27 |
| A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma Lenvatinib, Regorafenib (BAY 73-4506), Tislelizumab+TKI - Hepato Cellular Carcinoma (HCC) | Phase 2 | Recruiting | Fudan University | 350 | 2026-01-19 | 2026-04-21 |
| Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas Balstilimab, Botensilimab, Folfox Protocol - Gastric Cancer, MSI-H | Phase 3 | Recruiting | Centre Leon Berard | 132 | 2025-12-08 | 2026-06-25 |
| Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer SOX regimen, CAPEOX regimen, PD-1 inhibitor - Gastric Adenocarcinoma, Stomach Neoplasms | Phase 2 | Recruiting | Jinbo Yue | 54 | 2025-10-01 | 2026-10-15 |
| QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer QL1706, XELOX - Colon Cancer, MSS/pMMR | Phase 2 | Not yet recruiting | Qilu Hospital of Shandong University | 21 | 2025-09-25 | 2025-09-05 |
| Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study Long-course chemoradiotherapy, Tislelizumab combined with the CAPOX regimen, CAPOX regimen - Rectal Cancer | Phase 3 | Recruiting | Fudan University | 196 | 2025-08-12 | 2026-09-21 |
| Efficacy and Safety of AK112 Combined Chemotherapy as Neoadjuvant Treatment for Signet Ring Cell-containing G/GEJ Adenocarcinoma AK112+oxaliplatin+capecitabine, oxaliplatin+capecitabine - Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Peking Union Medical College Hospital | 66 | 2025-07-20 | 2025-07-29 |
| Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer Tislelizumab, SOX or CAPOX regimen - Gastric Cancer Stage | Phase 3 | Not yet recruiting | Xiangdong Cheng | 470 | 2025-07-20 | 2025-07-16 |
| Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer Trastuzumab biosimilars and pertuzumab biosimilars plus XELOX - Rectal Cancer, HER2-positive | Phase 2 | Recruiting | Peking Union Medical College Hospital | 24 | 2025-06-20 | 2025-08-06 |
| SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases short-course radiotherapy, CAPEOX/XELOX, Serplulimab - Colorectal Carcinoma, Oligometastases | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 51 | 2025-04-22 | 2026-03-25 |
| LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis Low Dose Radiotherapy, Short course Radiotherapy, XELOX - Colorectal Cancer, Liver Metastasis | Phase 1 | Recruiting | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 9 | 2025-02-28 | 2026-04-03 |
| Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme FOLFOX regimen, CAPOX regimen - Digestive Cancer, Colorectal Cancer | Phase 2 | Recruiting | UNICANCER | 400 | 2025-01-20 | 2026-04-23 |
Showing 20 of 113. Sign in to see all of them.
Colorectal Neoplasms (29) · Stomach Neoplasms (26) · Rectal Neoplasms (25) · Colonic Neoplasms (13) · Adenocarcinoma (3) · Neoplasm Metastasis (3) · Neoplasms (3) · Gastrointestinal Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Carcinoma (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Esophageal Neoplasms (1) · Gastrointestinal Diseases (1) · Intestinal Neoplasms (1)
Fudan University (9) · Harbin Medical University (4) · Sun Yat-sen University (4) · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (3) · Peking Union Medical College Hospital (3) · Shanghai Zhongshan Hospital (3) · Tang-Du Hospital (3) · Tianjin Medical University Cancer Institute and Hospital (3) · Asan Medical Center (2) · AstraZeneca (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · China Medical University, China (2) · Federation Francophone de Cancerologie Digestive (2) · GERCOR - Multidisciplinary Oncology Cooperative Group (2) · Henan Cancer Hospital (2)
China (67) · South Korea (10) · United States (9) · France (7) · United Kingdom (5) · Germany (4) · Italy (4) · Australia (3) · Poland (3) · Spain (3) · Argentina (2) · Canada (2) · Czechia (2) · India (2) · Japan (2)
Chuan Chen, MD PhD (2) · Jing Jin, M.D. (2) · Jingdong Zhang (2) · Xiaodi Zhao, MD, PhD (2) · Xin Wang, MD, PhD (2) · Xinxiang Li, MD,PhD (2) · Yuanyuan Lu, MD, PhD (2) · Ajay K Kakkar, PhD (1) · Alessio G Morganti, Professor (1) · Antonio Cubillo, MD PhaD (1) · Baocai Xing, MD (1) · Benoist Chibaudel, MD (1) · Binbin Cui, MD (1)
PMID 32251400, PMID 10493478, PMID 15867200, PMID 17442997, PMID 19406901, PMID 23062232, PMID 23510802, PMID 24523121, PMID 24905030, PMID 25424120, PMID 25460330, PMID 25471037, PMID 25538173, PMID 25822672, PMID 26028255, PMID 26141683, PMID 26646794, PMID 26808342, PMID 27053773, PMID 27754713, PMID 28150022, PMID 28241187, PMID 28426108, PMID 28797063, PMID 28881920, PMID 29620995, PMID 29727332, PMID 29976501, PMID 30089632, PMID 30922323, PMID 31239311, PMID 31451367, PMID 31513484, PMID 31724334, PMID 31729964, PMID 31771394, PMID 32108102, PMID 32164906, PMID 32167864, PMID 34713106, PMID 34792107, PMID 35174078, PMID 35382819, PMID 35623069, PMID 36306483, PMID 36870360, PMID 36914193, PMID 37724848, PMID 38022553, PMID 38051328
2018 (2), 2009 (1), 2017 (1), 2023 (1)